Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I can't wait to see the excuses for the latest rape of the bagholders.
What happened to the claim that they had plenty of cash?
The main business of this company is not selling cannabis, it is selling shares.
Aurora Strengthens Leadership Position in Germany with EU-GMP Certification at Preeminent Local Cannabis Production Facility
7:05 AM ET 5/18/22 | Dow Jones
State-of-the-art facility readying first delivery of medical grade cannabis for German patients
EDMONTON, AB, May 18, 2022 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the company has received EU-GMP certification for its state-of-the-art medical cannabis production facility in Germany. As a leading manufacturer of medical cannabis worldwide, achieving EU-GMP certification of the company's first German manufacturing site marks a significant milestone in the fulfillment of an awarded tender by the German Federal Institute for Drugs and Medical Devices (BfArM). Aurora is the distinct market leader in the German flower segment and will now leverage receiving the world's highest quality standard to produce and distribute premium medical cannabis in Germany.
The new state-of-the-art production facility in Leuna, Saxony-Anhalt, Germany adds to the company's pan-European network of EU-GMP facilities supplying premium, high-quality cannabis flower and extracts for medical use by patients across existing and expanding markets. Germany's medical cannabis market currently serves approximately 100,000 patients, representing only 0.1% of the population. In mature medical cannabis markets like Canada, market penetration is upwards of 1%, therefore the German market has significant potential for growth.
"With the EU-GMP certification of our first German site, we once again demonstrate Aurora's excellence and leadership in establishing the necessary infrastructure to compete in the global cannabis market," said Miguel Martin, CEO of Aurora Cannabis. "As a leading provider of medical cannabis in Germany and several other European markets, we are eager to accelerate patient access to high-quality, reliable cannabis produced in accordance with the most stringent criteria. Our first shipment from our world class Leuna facility will deliver on our commitment to the German regulatory authority and expanding patient base, a significant step in our ongoing commitment to international market growth."
Aurora was awarded a tender/contract in 2019 by the German Federal Institute for Drugs and Medical Devices (BfArM) for the annual production of 1,000 kg of high-quality medical cannabis flower over a period of four years. Despite numerous challenges due to ongoing pandemic-related restrictions and international supply chain bottlenecks, the construction of Aurora Leuna, a nearly 3,600 sq. metre production site is complete, has received its EU-GMP certification and is preparing for the inaugural shipment. The first shipment from Aurora Leuna to German pharmacies is expected via the state's cannabis agency later this month.
Martin continued "As a leading provider of cannabis flower and extracts in Germany, we are excited by the possibility of growth in the market. Our investment in domestic production with the highest quality standards will help advance patient access to high-quality cannabis. I congratulate our team in Germany on achieving this important milestone for our Leuna facility and the commencement of local production in this critical market."
As a leading global cannabis company with a footprint on four continents, sales into 12 countries, and an expansive international production network, Aurora celebrates this important milestone in the company's pursuit of enabling access to high-quality medical cannabis to patients worldwide.
About Aurora
Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, and Whistler, as well as CBD brands, Reliva and KG7. Medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Corp., and Pedanios. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on Twitter and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB" and is a constituent of the S&P/TSX Composite Index.
Forward-looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include statements regarding the production and distribution of premium medical cannabis in Germany, timing for the first shipment of cannabis from the Aurora Leuna facility to German pharmacies, competitive advantages including those related to EU GMP certification, and the Company's execution against its commitment to the German Federal Institute for Drugs and Medical Devices (BfArM). .
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated September 27, 2021 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-strengthens-leadership-position-in-germany-with-eu-gmp-certification-at-preeminent-local-cannabis-production-facility-301549911.html
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2022/18/c8136.html
/CONTACT:
For Media: Michelle Lefler, VP, Communications & PR, media@auroramj.com; For Investors: ICR, Inc., Investor Relations, aurora@icrinc.com
Copyright CNW Group 2022
> Dow Jones Newswires
May 18, 2022 07:05 ET (11:05 GMT)
Aurora Cannabis
@Aurora_MMJ
·
20h
Replying to
@Aurora_MMJ
The certification of Aurora Leuna marks a significant milestone in the fulfillment of a BfArM tender for the annual production of 1,000 kg of high-quality medical #cannabis flower over four years. The 1st shipment is expected via the state's cannabis agency later in May.
May be so, i would.not know. What troubles me a bit is a couple.or.more earnings ago he said sky running at 25% covered the cost to keep it open.
Yes, and besides, Canada is a costly place to grow good cannabis.
Too cold...
When Africa rises North America will tremble!
High end weed takes all the same effort to grow not so high end weed.
To me this sounds like bunk.
It doesn't cost a penny more to clone high-end weed.
This sounds a lot like selling fishing lures to fishermen.
The premium brands that are selling he said are moving to their other facilities
Nice and colorful. I too had my jaw drop to the floor when I read about sky. When I listened to the CC, and how they said it takes too long retooling, I'm not convinced if it's the management of the building or if it really is the cost to retool. If you also read between the lines as well as complaints over the years, Canada's government made too much red tape for exports, which, IMO, is why they have all these satellite locations in some places around the world to produce in other places. It really does suck, but makes sense. The right down is the sins of the past which is Morgan Stanley didn't figure that in. Also, in the CC, it sounds like sky could not produce THC levels high enough, which is like you said, didn't sell the volume. The premium brands that are selling he said are moving to their other facilities. They are now looking at a higher end of 150M in savings vs 60 to 80. This is probably why the stock is going up as one of the analysts was pretty excited about that as it's well past just being ebita positive if such happens.
Some Aurora data for all bag holders
AURORA CANNABIS $1 BILLION NET LOSS
CALEB MCMILLANMAY 15, 2022
To Bonno
Aurora Cannabis has announced net losses of $1 billion in the third quarter. They will be closing their Aurora Sky facility in Edmonton and two others in British Columbia.
Aurora says the move is an effort to make the LP “a leaner, more agile organization.”
The Aurora Sky facility is where Aurora employs 13 percent of its workforce. Aurora spokesperson Kate Hillyar declined to share how many people that included. Expect the facility to close by the third quarter of 2023.
The two BC facilities are Aurora Anandia and Whistler Alpha Lakes. Expect both to close by the end of the year.
How Did This Happen?
Aurora Cannabis is one of Canada’s largest LPs, so how exactly do they post a net loss of $1 billion?
Miguel Martin, Aurora’s chief executive, told analysts that the company suffered from excess inventory and fierce competition.
"Excess inventory". Read : bunk stays on shelves.
"Fierce competition". Read : Legacy kicks ass.
He called the market “irrational” but said, “We expect the recreational market in Canada to correct. When that process is complete, we will have added opportunities for market share and pricing.”
Correct for what? Read: Police will try to arrest their way through legacy.
In other words: we created this speculative market, we’re successfully weathering the storm, and once the market correction comes, we’ll be one of the few LPs left supplying Canadians with cannabis.
Aurora Cannabis Pulls a Hammer Time
Aurora Cannabis $1 billion
Aurora Cannabis losing $1 billion comes as no surprise. The company was never selling cannabis, according to one anonymous insider. “They were always just selling equity to bag holders.”
And nowhere is this more evident than Aurora Sky, their Edmonton grow facility that costs the company $7 million per quarter.
What ever happenned to scale?
The facility, designed to be a sea of green, was where computers and machines would automate everything. Giant cranes would handle the plants. No human hands needed to touch the cannabis.
But then consumers started buying the products. And they wanted premium brands and were willing to pay for them. Few wanted the mass-produced generic flower Aurora designed Aurora Sky for.
Aurora Sky is the equivalent of MC Hammer’s house. For those too young to remember, MC Hammer was a hip-hop artist in the 1980s. Successful beyond his wildest dreams, he bought a mansion to go with his fame. The house created headlines because, in the 1980s, spending $20 million on a home was unheard of.
But as MC Hammer’s hip-hop style dived in popularity, so did his album sales. And within a few years, he was declaring bankruptcy. Unable to afford the 40,000 sq ft house with Italian marble floors, a bowling alley, recording studio, two swimming pools, a movie theatre, tennis courts, a baseball diamond, and a 17 car garage.
Sound like a few cannabis company we know? One that hyped up its Aurora Sky facility. Even when the building was merely a concrete foundation on the eve of legalization?
Booth Makes Out Like A Bandit
Aurora Cannabis $1 billion
Terry Booth is an Edmonton electrician turned pot investor. Booth co-founded Aurora with $2.5 million of his own cash. Needing that kind of start-up capital shows what kind of legalization scheme the Trudeau government had created.
Booth never wore a suit to meetings. He was a workingman’s CEO, or at least that’s the image ascribed to him. A former employee says, “[A]s far as him being the CEO of a multi-billion-dollar company, you really got the feeling that was thrust upon him.”
Terry Booth resigned from Aurora in early 2020. The year prior hadn’t been good for the company. Aurora laid off a significant chunk of its employees, closed several facilities and saw its valuation drop by $1 billion.
Booth is now CEO of Australis, a Massachusetts-based cannabis investment firm. Like many other LP executives who inspired the Canadian market with false (some would even say fraudulent) confidence, he’s cut and run to the US.
Meanwhile, Aurora continues to lose money. “Aurora Cannabis posts a net loss of $1 billion” is becoming a typical headline.
The idea is that Aurora can afford to sell at a loss while the craft producers can’t. Over time, this leaves only the top LPs. This is the legacy of Terry Booth’s Aurora Cannabis and Justin Trudeau’s legalization scam.
Poor quality at a premium price nobody wants.
Nice green day! Morgan Stanley sees things as a break even as not looking at the sins of the past management, so taking that impairment out shows the true strengths. It really sucks sky is being sold off, hopefully with all the shortages we get a good price. As for Isreal, sounds like that is saturated now, so probably not anything soon(my opinion) but because we are growing, things are settling out. Awesome to see Australia's growing very strong and we are going above and beyond the cost savings. Listen to the CC to help understand the numbers and press releases to make your own decisions!
More declines:
Revenue down
Q3 2022 total cannabis net revenue was $50.4 million, down 17% sequentially.
"Adjusted" EBITDA worse than last quarter
Adjusted EBITDA loss declined to $12.3 million in Q3 2022 versus $9.0 million
https://investor.auroramj.com/news-and-events/press-releases/123011/
It just might take a quick drop to the $1.70s here soon.
If it's quick, I will be in for a trade. If it just keeps shedding it may never stop..
I remember 4 years back when the marijuana euphoria was in it's prime and this among other pot stocks were being pumped like no tomorrow and now look at this thing after a zillion for 1 stock split.
Why the "adjusted EBITDA positive" that ACB management has been touting for years doesn't matter, (from Uber):
"We have made a ton of progress in terms of profitability, setting a target for $5 billion in Adjusted EBITDA in 2024, but the goalposts have changed. Now it’s about free cash flow."
Even they recognize that the fiction of the phony "adjusted EBITDA" has been unmasked. There is no definition of "adjusted" so companies can make up whatever they want.
Free cash flow? Not with ACB. They get all their cash by selling shares. When ACB boasts about their balance sheet cash, they forget to mention it is all from selling shares, not product.
So here is the closing. I was never overly excited when they made this purchase. 12 people lost their job, so my guess is the license and land itself was the expense. Now we can sell it.
https://stratcann.com/2022/05/07/aurora-cannabis-closes-down-their-200-acre-bc-farm/
And as for the 180 acre property we just picked up(why the above is no longer needed).
https://thrivecannabis.ca/
http://crweworld.com/article/news-provided-by-pr-newswire/2374032/aurora-cannabis-to-host-third-quarter-fiscal-year-2022-investor-conference-call
I would be surprised if we get a surprise upside, but I bet it shows we are still on track. If you recall in his last conference call, I believe it was around August he figured the recreational would settle out. I'm hoping if the recreational market has rational prices then for 7s to profit, and its at that time we get aggressive with recreational again.
I have to hand it to you for hanging in there and posting. I’m like you a long suffering share holder. I’m praying this makes somewhat of a recovery even if it takes 5 years.
Maybe so. Aurora doesn't show signs of going under. I still believe and did buy more recently. I have a mix of long and short term shares, so it's going to be an interesting ride up when that starts. I feel we got beat up unnecessarily over the last 4 weeks. Tilray, in my opinion, put out earnings with a press release that was a bit creative in its language and again added some damage to the Canadian sector(trust). Also, we have an efficient manufacturing system too in not having crop loss as well.
Sure has been terrible for the long holder's, but I still believe. Ebita positive as he stated still stands. Hopefully profitable soon after. This below wad on Twitter a couple days ago.
"Aurora is expanding its #medicalcannabis portfolio in Germany with EU-GMP produced Dronabinol isolate, which is effective in alleviating neuropathic pain. Intended for oral use, Dronabinol will be available in German pharmacies as a prescription medication."
ACB is 1 of many I’m collecting
All in on MJ 2022
**** $ACB **** The pandemic saw a boom in legal recreational cannabis sales across Canada. From March 2020 to February 2021, sales totaled $2.5 billion, double the $1.25 billion of the previous 12 months.
https://theconversation.com/the-pandemic-had-little-impact-on-canadas-legal-cannabis-sales-180206
Need the Big Boys to start eyeing their future slice of the pie. Coke, Budweiser, Phillip Morris, they'll all want some exposure in this space and I believe 2022 is the year we see them do it
Lock n' Load
Seems like a broken stock. It's been good for traders on several occasions, but for longs, virtually disastrous.
The ability to show a profit is paramount. Anything less is tantamount to disaster at this stage.
Shakeup needed..
EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End
2 hours ago, 4:00 PM EDT
Via Benzinga
Stocks mentioned: ACB
Any TA guru that can talk to his "potential" claim of skyrocketing in the near future? I'd be interested in hearing people's opinions.
I sure would complain!
U.S. Senate votes to expand cannabis research
Updated: Mar. 26, 2022, 10:51 p.m. | Published: Mar. 26, 2022, 3:29 p.m.
EDITOR’S NOTE: NJ Cannabis Insider is co-hosting a Cannabis Career Fair & Business Expo on April 5 at Stockton University. (Students free.) Tickets here.
A unanimous U.S. Senate has voted to expand research into cannabis to see if there are any medical benefits to the drug and its compounds, including cannabidiol.
The Cannabidiol and Marihuana Research Expansion Act also would require the U.S. Department of Health and Human Services and the National Institutes of Health to report to Congress on the potential benefits or harms associated with using cannabis.
https://www.nj.com/marijuana/2022/03/us-senate-votes-to-expand-cannabis-research.html
Legalization 2.0: Massachusetts Senate approves overhaul of marijuana laws...
The Massachusetts Senate on Thursday unanimously approved the most significant changes to the state’s marijuana laws since legalization was implemented in 2017.
The package of reforms would crack down on excessive fees charged by municipalities to licensed marijuana operators, clear the way for cities and towns to approve cannabis cafes, and put more muscle behind policies meant to make the licensed pot industry equitable after decades of racially disproportionate drug arrests.
“With this bill, Massachusetts will reclaim our leadership role, carving a path to make equity a reality in the cannabis industry,” said state Senator Sonia Chang-Diaz, a Democrat, who championed the legislation as co-chair of the Legislature’s Joint Committee on Cannabis Policy. “Lowering entry costs and opening up new avenues to capital will put this multibillion-dollar industry within reach for many talented equity entrepreneurs.”
https://www.msn.com/en-us/news/politics/legalization-20-massachusetts-senate-approves-overhaul-of-marijuana-laws/ar-AAVYHqZ
Aurora to $5 tomorrow!?..
SOBs fking it up, constantly, min by min, hr by hr day after day, manipulating all Cannabis/hemp/cbd stocks, they are not learning lesson how fast cannabis stocks can run high when it does!!...Congress to Senate vote was a huge fked up manipulative event and hence whole sector was crashed again since it tried to rally couple weeks ago due to the voting event, the same voting event turned as buy rumor sell news by mainstream fking media talking senate vote may this and may that...fk!...sector now is in that perilous down fall, but watch out for a real turn around coming soon!!
Aurora Cannabis Inc is a vertically integrated cannabinoid company that caters to the medical and consumer markets. The stocks are traded under the symbol ‘ACB’. The company was incorporated as Milk Capital Corp on December 21, 2006. Aurora Cannabis Inc (TSX: ACB) created a buzz in the Canadian market on Tuesday after it announced to acquire TerraFarma Inc, which owns Thrive Cannabis.
Noticing some higher management leaving Aurora Europe. Might not be a bid deal, I have not looked around to make assumptions why... just Noticing one left in January and another in March. Because they didn't have a break in work, my guess is they left.
Baa. Maybe I shouldn't have said anything
Should be another good week. Being acb is focused on medical, we may have certain advantages with the bill that imo Should pass.
Very good indeed
Over $5.00 AH-- crazy =)
*I didn't hit the bottom (it dropped down $2.78 after I bought) At that point I backed away and didn't look till the open, and my joy =)
I didn't hit the top either, and kept a few with stops @3.24
It appears to be leveling out. So, we wait =)
*I just set alerts on stocks I follow. I got an alert, saw the big dip, didn't see anything wrong more than usual (to keep everyone happy).
Seems so, that news did not occur when I made my breakout alert..!. May be end of day news I think, but it had a after hour spike to$4 and above, todays close will be above 4!.
6k filed on the pr too.
https://sec.report/Document/0001279569-22-000406/
Man, if you are still holding, you're doing awesome!
really nice things going on. Seems the new ceo continues to do what he says.
So in the press release that came out a but ago...
"Transaction will provide immediate positive Adjusted EBITDA to Aurora, and support the Company's path to Adjusted EBITDA profitability in the first half of fiscal 2023."
printFont size A A A
Aurora Cannabis Advances Premiumization Strategy by Acquiring Thrive Cannabis, and its Award-Winning Greybeard Brand, in a Margin Accretive Transaction
6:06 PM ET 3/22/22 | Dow Jones
-- Thrive's highly experienced and trusted cannabis team in craft
cultivation, product innovation, and operational execution will lead
Aurora's Canadian recreational business
-- Expands Aurora's brand offering with Greybeard, an award-winning,
super-premium, high margin brand regarded for its budtender appreciation
-- Transaction is expected to close in Aurora's Q4 fiscal 2022, contribute
immediate positive EBITDA and support Aurora's goal to reach EBITDA
profitability in the first half of fiscal 2023
NASDAQ | TSX: ACB
EDMONTON, AB, March 22, 2022 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, is pleased to announce today that the Company has reached an agreement to acquire all of the issued and outstanding shares of TerraFarma Inc. (parent company of Thrive Cannabis) ("Thrive") (the "Transaction"). The Transaction is based upon aggregate consideration of $38 million (the "Initial Consideration") payable in cash and Aurora common shares ("Aurora Shares"), plus two earnout amounts (the "Earnout Consideration") payable in Aurora Shares or cash (at the election of Aurora), if applicable, based on Thrive achieving certain revenue targets within two years of closing of the Transaction.
The Transaction is expected to strategically strengthen Aurora's position in the Canadian market by placing the Thrive team in charge of Aurora's Canadian recreational portfolio, advancing the shift in focus to innovative premium products including dried flower, pre-rolls, vapour products, and concentrates. The Transaction is expected to close, subject to customary closing conditions, in Aurora's fiscal Q4 2022. It is anticipated that the Transaction will provide immediate positive Adjusted EBITDA to Aurora, and support the Company's path to Adjusted EBITDA profitability in the first half of fiscal 2023.
Founded in 2018, Thrive is a licensed producer of super-premium cannabis concentrates and craft dried flower, and leverages innovative cultivation and extraction techniques with a singular focus on achieving the highest quality standards. Thrive is most widely known for its award-winning flagship recreational brand, Greybeard Cannabis Co. ("Greybeard"), which amongst other accolades was recognized as the #1 brand recommended by Canadian budtenders in 2021, and was the 2021 winner of Best Concentrate from the Kind Magazine Awards, as voted for by budtenders.
Management Commentary
"As consolidation among licensed producers accelerates, it's vital that any transactions we make, now or in the future, be strategic, accretive, and centred around adding exceptional talent and brands that align with our path to profitability," said Miguel Martin, Chief Executive Officer of Aurora. "In these respects, Geoff and the Thrive team have a track record seldom found elsewhere in the Canadian market. They are truly exceptional cultivators who have gained trust with consumers and developed products that have been recognized and acclaimed by Canadian budtenders and industry peers. We see a unique opportunity to leverage their expertise to deliver near and long-term benefits for both our recreational and medical markets," he continued.
"This transaction supports our path to profitability while ensuring that we are strategic in our M&A activity. Thrive's achievement of positive standalone EBITDA, combined with their exceptional operational and brand capabilities, truly set them apart, and we look forward to leveraging their expertise as we embark together on Aurora's path to profitability, " he concluded.
"We are excited to be joining a team that shares our vision for delivering the highest quality, premium cannabis products to consumers in a way that generates sustainable profitability," said Geoff Hoover, Chief Executive Officer of Thrive. "We look forward to combining our best-in-class products and innovation pipeline with Aurora's depth of operational capabilities, robust route to market and shared focus on superior science and genetics that is critical for advancement in this sector. This combining of two great companies will be transformative."
Strategic Rationale
Supports Aurora's Timeline to Profitability with Positive and Growing EBITDA: Transaction is aligned with Aurora's plan to achieve profitability in H1/FY23 on an Adjusted EBITDA basis. Thrive has achieved positive standalone EBITDA in the last 12 months ended December 2021, with additional cost synergies expected to drive further EBITDA growth.
Acquisition of Two Leading Cannabis Brands Synonymous with Quality & Consistency: Thrive adds two new brands to Aurora's portfolio, both of which have rapidly gained market share over the last twelve months and are expected to flourish with additional resources on Aurora's platform:
Greybeard is an ultra-premium, high-terpene, high-potency brand with a world class lineup of concentrates that has quickly developed recognition with budtenders and cannabis connoisseurs. Concentrates are produced using a proprietary hydrocarbon extraction and refining process that maximizes the cannabinoids and terpene content, resulting in aromatic and flavourful products that highlight the unique characteristics of each strain. Greybeard also utilizes industry leading cultivation practices to offer super-premium, small batch, AAAA quality dry flower and pre-rolls, featuring large pristine buds grown in its indoor facilities.
Being Cannabis is a wellness-oriented brand known for their sublingual THC and CBD strips. These fast-acting and precisely dosed sublingual strips dissolve under the tongue and don't require any accessories or preparation.
Addition of Highly Experienced Management Team with Leading Operational and Cultivation Expertise: Transaction will add a talented management team comprised of industry veterans with leading cannabis cultivation, extraction, and product development expertise. The Thrive team leading Aurora's Canadian recreational business will drive significant improvements to the consistency, quality, and yield of Aurora's cannabis products across the portfolio.
Robust Product Pipeline Led by Expansive Genetics Library: Thrive brings a genetics library that has consistently delivered 24%+ THC potency, high yielding (80g+ / plant) and disease-resistant cultivars. These new cultivars, along with various SKUs in the development pipeline for Greybeard and Being, will deliver innovative and on-trend products to Canadian consumers.
Transaction Details and Timing
The Transaction will be effected by way of a three-cornered amalgamation whereby Thrive will amalgamate with a wholly-owned subsidiary of Aurora resulting in Aurora owning all of the issued and outstanding shares of the amalgamated entity in exchange for the Initial Consideration to be issued to Thrive shareholders on a pro rata basis at deemed price per Aurora Share equal to the volume weighted average trading price ("VWAP") of Aurora Shares on the Toronto Stock Exchange ("TSX") for the 5 trading days immediately prior to the second business day prior to the effective date of the Transaction. The sum of $3 million of the Initial Consideration is subject to a holdback to be released on the 18-month anniversary of the closing of the Transaction subject to adjustment for any indemnification claims. The Earnout Consideration consists of up to $10 million for satisfying certain near-term revenue targets and up to $20 million for satisfying certain long-term revenue targets within 2 years of the closing of the Transaction, each payable in cash, Aurora Shares or a combination of both (at the election of Aurora).
The number of Aurora Shares to be issued under the Earnout Consideration, if any, will be calculated based on a deemed price per Aurora Share equal to the VWAP of Aurora Shares on the TSX for the 5 trading days immediately prior to the applicable earnout payment date.
The Transaction is subject to receipt of regulatory, third party and Thrive shareholders' approvals and other customary closing conditions and expected to close in Aurora's fiscal Q4 2022. Lazard Canada Inc. is acting as exclusive financial advisor to Aurora in connection with the Transaction. McMillan LLP is serving as legal counsel to Aurora.
About Aurora Cannabis
Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, and Whistler, as well as CBD brands, Reliva and KG7. Medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, and Pedanios. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on Twitter and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB" and is a constituent of the S&P/TSX Composite Index.
About Thrive Cannabis
Founded in 2018, Thrive Cannabis is a vertically integrated cannabis company based in Simcoe, Ontario. Thrive is most widely known for its award-winning flagship adult-use brand, Greybeard Cannabis Co., which specializes in premium quality, small-batch craft cannabis concentrates and flower products. Thrive is also known for its adult-use wellness-oriented brand, Being. The Thrive team leverage their expertise in cannabis cultivation, extraction and product development with a singular focus on delivering the highest quality standard products to consumers. Learn more at www.thrivecannabis.ca.
Forward Looking Information
(MORE TO FOLLOW) Dow Jones Newswires
March 22, 2022 18:06 ET (22:06 GMT)
Wow... at last!!..
Hello Longs!..you are going to put up that smile soon!..
Here is the breakout alert for Aurora!... Enjoy!.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168296038
You had great timing on that purchase! I know if I purchase then I'd be struggling with the question today....should I cover a bit of the cost base at this point. I've not seen anything to indicate why the drop or the rise... but I've been swamped with my normal work.
(sic) Is that DL subterfuge for shoulda-woulda-coulda?
Quote:
"for strategical things like aquasitions(sic)"
To be fair, it was $100k CDN=)
Woot!
This is nice and ancient.
How 'bout you modernize it in lieu of 3 day old fish concerns?
Yeah, but that is also why people are bullish as they feel it's going to get reclassified, being studies are coming out showing medical value.
Followers
|
894
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
70346
|
Created
|
11/09/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |